

WHO Working Group – Target Product Profiles for COVID-19 Vaccines

Preparations for delivery

Overview

The current global nCoV public health emergency underscores the need to accelerate the development of nCoV candidate vaccines. The Working Group on Target Product Profile for vaccines against COVID-19 aims to provide guidance from an end-to-end perspective. The objectives of this group are:

- To develop a global target product profile (TPP) for vaccines against COVID-19.
- The TPP will include preferred and minimally acceptable profiles for two vaccines:
 - Human vaccine – for long term protection of persons at high ongoing risk of COVID-19 such as healthcare workers.
 - Human vaccine – for reactive use in outbreak settings with rapid onset of immunity.
- To prepare and be available for the regular working group calls.
- To provide technical advice and support the WHO Secretariat through comments and or feedback from stakeholders.

Criteria for COVID-19 vaccine prioritization

Overview

Purpose of the document

The proposed attributes and criteria provide considerations for the evaluation and prioritization of COVID-19 candidate vaccines to be considered for further development by WHO. The target audience includes vaccine scientists, product developers, manufacturers, regulators and funding agencies.

The attribute and criteria below lay out some of the considerations that structure WHO's case-by-case assessments of COVID-19 vaccines in the future, with emphasis on prioritization for Phase IIb/III evaluation.

Criteria that are considered of major importance in ranking the vaccines are reported in bold in the table. WHO will also provide a scoring guide to promote consistency and predictability of evaluation.

Source: www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines